Axinn Granted Summary Judgment in Delaware Federal Court
June 24, 2014
Law360
A Delaware federal judge on June 24 granted summary judgment to Axinn client Alvogen in a lawsuit brought by Novartis AG over a generic version of the Exelon dementia treatment patch. After the close of fact discovery, Novartis granted a covenant not to sue to Alvogen.
Click here to read about the judgment in Law360’s article.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
ACI Forum on Pharma & Biotech Patent Litigation USA 2025
Speaking Engagement
Intellectual Property
CCWC 21st Annual Career Strategies Conference
Speaking Engagement
Fordham 52nd Annual Conference on International Antitrust Law and Policy
Speaking Engagement
Antitrust
Kisaco Research Trade Secret Legal Protection Conference 2025
Speaking Engagement
Intellectual Property
SCCE 23rd Annual Compliance & Ethics Institute
Speaking Engagement
Antitrust
29th Annual IBA Competition Conference
Sponsorship
Antitrust
Key Appellate Decisions Shaping Antitrust Strategy
Webinar
Antitrust
New Frontiers of Antitrust – 16th Annual International Conference of Concurrences Review
Speaking Engagement
Antitrust
MCCA Pathways Conference
Sponsorship
Antitrust
HNBA/VIA Annual Convention 2025
Sponsorship
Antitrust